8

10

11

12

13

14

15

16

17

18

19

20

21

22

23

26

27

28

DRINKER BIDDLE & REATH LLP 50 Fremont Street, 20th Floor San Francisco, CA 94105

385883v1

Simpson Eldredge Hersh Jardine PC filed a wrongful death action in the Superior Court

of California, County of San Francisco, entitled Terri Randall v. Ortho-McNeil

DRINKER BIDDLE & REATH LLP 50 Fremont Street, 20th Floor San Francisco, CA 94105

#385883 v1

Pharmaceutical, Inc., McKesson Corp., and Does 1-500, inclusive, Case Number CGC-07-463332. A copy of the Complaint in that San Francisco County state court action (the "Complaint") is attached as Exhibit A to the accompanying Declaration of Brenda N. Buonaiuto ("Buonaiuto Dec.").

The plaintiff in that action is a resident of Baltimore, Maryland, who seeks damages for the death of India C. Aziz, allegedly caused by decedent's use of the Ortho Evra® contraceptive patch, available only by prescription and manufactured by OMP. (Complaint ¶ 1-2, 11.) Plaintiff alleges causes of action for Negligence, Strict Liability Failure to Warn, Breach of Express Warranty, Breach of Implied Warranty, Negligent Misrepresentation, Fraud, and Wrongful Death against OMP, a Delaware corporation with its principal place of business in New Jersey.¹ (Complaint ¶ 12; Buonaiuto Dec. ¶ 3.) Although devoid of any factual allegations against McKesson, plaintiff's Complaint asserts those same claims against that defendant, a Delaware corporation with its principal place of business in San Francisco, California, whom plaintiff, a Maryland resident, alleges "distributed and sold Ortho Evra in and throughout the State of California." (Complaint ¶ 4, 17; Declaration of Greg Yonko, filed in *Abel, Theresa, et al. v. Ortho-McNeil Pharmaceutical, Inc., et al.*, USDC ND CA Case No. C 06 7551 SBA ("Yonko Dec."), attached to the Buonaiuto Dec. as Exhibit B, ¶ 2.)

BASIS FOR JURISDICTION

2. <u>Basis for Jurisdiction in this Court</u>. This Court has original jurisdiction over this action, and OMP may properly remove to this Court, because the amount in controversy exceeds \$75,000, exclusive of interest and costs and there is diversity of citizenship of all named parties. 28 U.S.C. §§ 1332, 1441(a). Although McKesson is a resident of the forum, the forum defendant rule does not prevent this Court from taking jurisdiction of this action. *Lively v. Wild Oats Markets, Inc.*, 456 F.3d 933 (9th Cir. 2006)

¹ Although plaintiff alleges that she is "the proper party to maintain this action," she failed to file a sworn successor in interest affidavit or declaration, as required by Cal. Civ. Proc. Code Section 377.32, and OMP reserves its objection to this defect.

(holding that forum defendant rule limitation on diversity-based removal jurisdiction is a procedural, or non-jurisdictional, rule). Further, because McKesson was fraudulently joined, that rule should not apply.

4

3

5

6 7

8

9

10 11

12

13

1415

16

17

18 19

20

2122

23

24

25

26

27

28 VKER BIDDLE & REATH LLE

DRINKER BIDDLE & REATH LLP 50 Fremont Street, 20th Floor San Francisco, CA 94105

#385883 v1

a. Amount in Controversy. Pursuant to California Code of Civil Procedure Section 425.10(b), the amount of damages sought by plaintiff is not stated in the Complaint. However, plaintiff alleges that her decedent "suffered death as a result of ingestion of [Ortho Evra®]." (Complaint ¶ 2; see also ¶ 11.) Plaintiff further alleges that OMP engaged in "fraudulent" and "reckless" conduct, giving rise to punitive damages claims. (See e.g. Complaint ¶¶ 49, 52D, 63E, 64, 76, 82E, 91, 102.)

Based on a review of damages awards and settlement amounts in this judicial district, in cases involving allegations of death from the use of prescription drugs or medical devices, it is reasonably believed that, if plaintiff succeeded in proving the allegations of her Complaint, she would recover a minimum of \$75,000 in damages. (Buonaiuto Dec. ¶ 10.) Indeed, plaintiffs in the Ortho Evra® MDL have specifically alleged that the amount in controversy in their respective actions exceeds \$75,000, exclusive of interest and costs. (*Id.*)

It is therefore "facially apparent" from the nature of the claims alleged and the types of damages sought that the amount in controversy in this action exceeds \$75,000, exclusive of interest and costs. See White v. FCI USA, Inc., 319 F.3d 672, 674 (5th Cir. 2003) (it was "facially apparent" that claim exceeded \$75,000 based on plaintiff's "lengthy list of compensatory and punitive damages"); see also In re Rezulin Products Liability Litigation, 133 F.Supp.2d 272, 296 (S.D.N.Y. 2001) (concluding that complaint "obviously asserts a claim exceeding \$75,000" where plaintiff seeks "compensatory and punitive damages" for alleged "serious and life-threatening medical conditions" due to use of prescription medicine); International Padi, Inc. v. Diverlink, 2005 WL 1635347, *1 (9th Cir. Cal. 2005) (court considered plaintiffs' general allegations of unspecified general and special damages "reasonably believed to be in excess of the jurisdictional limits" of the trial court and their request for injunctive relief to "easily conclude" that the

- b. <u>Citizenship of the Parties</u>. There is complete diversity of citizenship between the parties, pursuant to 28 U.S.C. Section 1332. As alleged in the Complaint, plaintiff is a citizen of Maryland. (Complaint ¶ 11.) At the time the state court action was filed and at the time of this removal, OMP was and is a corporation existing under the laws of the State of Delaware, with its principal place of business in New Jersey, and McKesson was and is a corporation existing under the laws of the State of Delaware, with its principal place of business in California. (Buonaiuto Dec. ¶ 3; Yonko Dec. ¶ 2.)
- Given that the forum defendant rule is procedural and not jurisdictional the fact that McKesson has its principal place of business in San Francisco does not prevent removal of this action. *See, Wild Oats, supra.* Further, the Court should disregard the rule, as plaintiff fraudulently joined McKesson as a "sham" defendant, solely in an effort to invoke the rule and to prevent OMP from removing the action to federal court and then transferring it to the Ortho Evra® MDL.

A defendant is fraudulently joined if "the plaintiff fails to state a cause of action against the defendant, and the failure is obvious according to the settled rules of the state." Morris v. Princess Cruises, Inc., 236 F.3d 1061, 1067 (9th Cir. 2001). "When determining whether a defendant is fraudulently joined, "[t]he court may pierce the pleadings, consider the entire record, and determine the basis of joinder by any means available." Maffei v. Allstate California Ins. Co., 412 F.Supp.2d 1049 (E.D.Cal. 2006), citing Lewis v. Time, Inc., 83 F.R.D. 455 (E.D.Cal. 1979) ("it is well settled that upon allegations of fraudulent joinder ... federal courts may look beyond the pleadings to determine if the joinder ... is a sham or fraudulent device to prevent removal"). If revealed that the joinder is fraudulent, the Court may dismiss the sham defendant. Maffei, supra. McKesson is so fraudulently joined here.

McKesson is fraudulently joined because plaintiff has not made any material allegations against it. See e.g. Brown v. Allstate Insurance, 17 F.Supp.2d 1134, 1137

DRINKER BIDDLE & REATH LLP 50 Fremont Street, 20th Floor

#385883 v1

2 3 4

1

6

8

10 11

1213

14

15

16 17

18

19 20

21

22

2324

25

2627

RINKER BIDDLE & REATH LLP :
0 Fremont Street, 20th Floor an Francisco, CA 94105

#385883 v1

(S.D.Cal. 1998) (finding in-state defendants fraudulently joined where "no material allegations" against those defendants were made). Here, as demonstrated by the Complaint, plaintiff's claims are substantively directed against the manufacturer of Ortho Evra® – OMP, and not at McKesson. Indeed, none of plaintiff's factual allegations, on which all of her causes of action are based, involve McKesson. (See "General Allegations" at Complaint ¶¶ 25-40.)

Plaintiff claims that: OMP obtained FDA approval of Ortho Evra®, despite concerns about its safety; OMP failed to appropriately warn users and prescribing health care providers of the alleged serious risks of using Ortho Evra®; OMP failed to properly or adequately investigate safety concerns about Ortho Evra®; OMP's conduct fell below the duty of care that it allegedly owed to plaintiff (which plaintiff presumably meant was allegedly owed to her decedent); OMP misrepresented the known risks associated with Ortho Evra®; OMP negligently and recklessly failed to inform the public and prescribing health care providers of the alleged risks of using Ortho Evra®; and OMP was careless and negligent in its manufacturing, testing, selling, distributing, merchandising, advertising, promoting, packaging, and marketing of Ortho Evra®. (Id.) Those allegations have everything to do with the claimed acts and omissions of OMP, and nothing to do with McKesson.

The only factual allegations that do relate to McKesson fail to state a claim against that defendant. Plaintiff alleges that McKesson "distributed and sold Ortho Evra in and throughout the State of California," and that McKesson "packaged, distributed, supplied, sold, placed into the stream of commerce, labeled, described, marketed, advertised, promoted and purported to warn or to inform users regarding the risks pertaining to, and assuaged concerns about the pharmaceutical Ortho Evra." (Complaint ¶¶ 4, 20.) Notably absent is any allegation that plaintiff's decedent fell within the general class of "users"

² As detailed in its Answer, filed simultaneously with this Removal, OMP denies plaintiff's allegations and denies that it is liable to plaintiff in any manner or sum whatsoever.

17.

NKER BIODLE & REATH LLP Fremont Street, 20th Floor Francisco, CA 94105

#385883 v1

referenced by plaintiff's conclusory allegations. Even more telling, plaintiff does not allege that McKesson distributed or sold Ortho Evra® to her decedent or to any of her decedent's health care providers or pharmacists. (See Complaint.) Further, the Complaint lacks any allegation that McKesson sold or distributed Ortho Evra® outside the State of California, where plaintiff's decedent presumably lived. See 28 U.S.C. § 1332(c)(2) (providing, in part, "the legal representative of the estate of a decedent shall be deemed to be a citizen only of the same State as the decedent"). The absence of such allegations compels the conclusion that plaintiff fraudulently joined McKesson. See e.g. Lyons v. American Tobacco Co., 1997 WL 809677 at *5 (S.D. Ala. 1997) (holding that there is "no better admission of fraudulent joinder" than the failure of plaintiff "to set forth any specific factual allegations" against the joined defendant).

In short, plaintiff fails to allege that her decedent received Ortho Evra® sold or distributed by McKesson, a prerequisite to her product liability claims. It is essential that a plaintiff who claims that a product distributed by defendant was defective must prove that defendant was the distributor. *Garcia v. Joseph Vince Co.*, 84 Cal.App.3d 868, 874 (1978) ("Regardless of the theory which liability is predicated upon ... it is obvious that to hold a producer, manufacturer, or seller liable for injury caused by a particular product, there must first be proof that the defendant produced, manufactured, sold, or was in some way responsible for the product"). Notwithstanding, given that the crux of plaintiff's claims is an alleged failure to warn of the alleged risks of using Ortho Evra®, there is no legal basis for the causes of action asserted against McKesson.

Under California law, McKesson bears no duty to warn. Rather, the "learned intermediary doctrine" provides that the duty to warn of a drug's risk runs from the manufacturer to the physician, and then from the physician to the patient. See Brown v. Superio Court (Abbott Labs.), 44 Cal.3d 1049, 1061-62, n.9 (1988); Carlin v. Superior Court (Upjohn Co.), 13 Cal.4th 1104, 1116 (1996). The rationale of the learned intermediary doctrine is that the physician is in the best position to determine whether a patient should use a prescription drug, and imposing a duty to warn on others would

28
RINKER BIDDLE & REATH LLP
Fremont Street, 20th Floor
on Francisco, CA, 94105

#385883 v1

threaten to undermine reliance on the physician's informed judgment. For this reason, California courts have rejected imposing liability on distributors, including specifically McKesson, for failure to warn of the risks of using a prescription drug. See e.g. Barlow v. Warner-Lambert Co., Case No. CV-03-1647-R(RZx), Slip Op. at 2 (C.D.Cal. April 28, 2003) (attached as Ex. C to the Buonaiuto Dec.) ("the Court finds that there is no possibility that plaintiffs could prove a cause of action against McKesson, an entity which distributed [the prescription medication at issue] to pharmacists in California;" motion to remand denied); and Skinner v. Warner-Lambert Co., Case No. CV-03-1643-R(RZx), Slip Op. at 2 (C.D.Cal. April 28, 2003) (attached as Ex. D to Buonaiuto Dec.) (same).

Further, McKesson had no involvement in the development or preparation of the prescribing information for Ortho Evra® and did not have any responsibility for the content of other written warnings concerning Ortho Evra®. (Yonko Dec. ¶ 5.) At no time has McKesson had any involvement with the manufacture, development, testing, packaging, labeling, advertising, promotion, or marketing of Ortho Evra®. (Id. ¶¶ 6-7.)

It is therefore a mystery why McKesson is named in this case, other than as a "sham" defendant to prevent OMP from removing the action to federal court and then transferring it to the Ortho Evra® MDL. Courts have consistently ruled that such collusive tactics are not to be recognized. See e.g. Attorneys Trust v. Videotape Computer Products, Inc., 93 F.3d 593 (9th Cir. 1996) (noting there is no more reason for federal courts to countenance destruction of jurisdiction by the use of straw parties than there is for them to countenance the creation of jurisdiction in that manner); Grassi v. Ciba-Geigy, Ltd., 894 F.2d 181, 185 (5th Cir. 1990), citing American Law Institute, Study of the Division of Jurisdiction Between State and Federal Courts, Official Draft, at 169 (1969) ("Removal based on diversity of citizenship is a right conferred by Congress, the need for which 'may well be greatest when the plaintiff tries hardest to defeat it."").

d. <u>Citizenship of Doe Defendants</u>. Pursuant to 28 U.S.C. Section 1441(a), for purposes of removal, the citizenship of defendants Does 1-500 must be disregarded because plaintiff sued those defendants under fictitious names.

2

3

5

6 7

8

9

11

12

13

14 15

16

17

18 19

20

21₂₂

23

24

25

26

27

28

DRINKER BIDDLE & REATH LLP 50 Fremont Street, 20th Floor San Francisco, CA 94105

#385883 v1

REMOVAL TIMELY FILED

3. Service was made on OMP's registered agent for service of process on June 12, 2007. (Buonaiuto Dec. ¶ 3.) McKesson was served, via its registered agent, on June 20, 2007. (*Id.* ¶ 4.) Therefore, this Removal was timely filed within 30 days of service, pursuant to 28 U.S.C. § 1446(b).

CONSENT TO REMOVAL

4. The only other named defendant, McKesson, was fraudulently joined, and its consent is therefore not required for removal; notwithstanding, McKesson consents to OMP's removal of this action to this Court. (Buonaiuto Dec. ¶ 4.)

STATE COURT WITHIN THE COURT'S JURISDICTION

5. The San Francisco County, California Superior Court, from which OMP removes this action, is within this Court's jurisdiction.

STATE COURT PLEADINGS

6. Copies of the state court pleadings known to OMP to have been filed in this action are collectively attached to the Buonaiuto Dec. as Exhibit A.

FILING AND SERVICE OF NOTICE OF REMOVAL AND REMOVAL

7. OMP will file a notice of the filing of this Notice of Removal and Removal in the San Francisco County Superior Court and will serve plaintiffs' counsel with a copy. (Buonaiuto Dec. ¶ 5.)

WHEREFORE, OMP hereby removes to this Court San Francisco County Superior Court Case No. CGC-07-463332.

Dated: June 29, 2007

DRINKER BIDDLE & REATH

BRENDA N. BUONAIUTO

Attorneys for Defendants

ORTHO-MCNEIL PHARMACEUTICAL,

INC. and MCKESSON CORPORATION